Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8452W HIGH $4.31
Volume
8.18 M
Value Traded
743.34 K
Short % Float
7.82%
+18.68%Week
+142.4%1 Month
+31.71%3 Month
-30.88%6 Month
-77.89%5 Year
-77.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
274.87 M
EPS (TTM)
-0.44
P/E Ratio
-
Ent. Value
145.69 M
Total Shares
127.26 M
Float Shares
73.83 M
Insiders
41.98%
Institutions
32.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NAUT Catalyst Timeline
Dated clinical, regulatory and corporate events for Nautilus Biotechnology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nautilus Biotechnology, Inc.
109Total events
15Upcoming
12Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Recognized grant revenue from Michael J. Fox Foundation for alpha-synuclein proteoform assay development
Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Nautilus management presentation at Investor Summit Group Virtual Conference
▲Partnership / LicenseCorporate
Baylor College of Medicine selected as first Early Access Program customer for Voyager Platform
cancersource ↗
◆Oral PresentationPresentation
Nautilus management to participate in fireside chat at TD Cowen 46th Annual Health Care Conference
▲Runway Guidance UpdateCorporate
Cash runway guidance: sufficient to fund operations through 2027
◆Oral PresentationPresentation
Oral presentation on advancing proteomics through Iterative Mapping at US HUPO 2026
◆Poster PresentationPresentation
Poster detailing tau proteoform analysis in Alzheimer's disease at US HUPO 2026
Alzheimer's diseasesource ↗
▲Partnership / LicenseCorporate
Research collaboration with Weill Cornell Medicine-Qatar and MJFF to study alpha-synuclein proteoforms in Parkinson's disease
Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Webinar on single-molecule Iterative Mapping with Buck Institute data
▲Product LaunchPost-Market
Launch of Early Access Program for proteomics platform with tau proteoforms assay
▲Platform ValidationPreclinical
Initiated Iterative Mapping Early Access Program with Baylor College of Medicine for Tau proteoform assay
◆Oral PresentationPresentation
Redefining Proteomics with Single-Molecule Iterative Mapping at HUPO 2025
Alzheimer's diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
Successful installation and testing of first external field evaluation unit at Buck Institute
▲Partnership / LicenseCorporate
Agreement with Allen Institute to investigate tau proteoforms in Alzheimer's disease
Alzheimer's diseasesource ↗
●PreprintPresentation
Preprint on single-molecule analysis of tau proteoforms
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Nautilus management fireside chat at Goldman Sachs 46th Annual Global Healthcare Conference
▲PublicationPresentation
First scientific manuscript featuring novel data generated using Nautilus Platform publicly shared
▲Partnership / LicenseCorporate
Signed two collaborations with major research institutes to utilize Nautilus platform and Tau proteoform assay
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Nautilus management to participate in fireside chat at TD Cowen 45th Annual Healthcare Conference
▲Runway Guidance UpdateCorporate
Cash runway expected through planned launch and well into 2025
◆Oral PresentationPresentation
Nautilus management to participate in fireside chat at Guggenheim Healthcare Conference
◆Oral PresentationPresentation
Nautilus management fireside chat at Morgan Stanley 22nd Annual Global Healthcare Conference
◆Oral PresentationPresentation
Nautilus management to participate in Goldman Sachs 45th Annual Healthcare Conference fireside chat
◆Product LaunchPost-Market
Anticipated launch of Nautilus proteome analysis platform by mid-2024
◆Product LaunchPost-Market
Planned platform launch (instruments, reagents, software) in mid-2024
◆Oral PresentationPresentation
Morgan Stanley 21st Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Management to host 1x1 investor meetings at UBS MedTech, Tools and Genomics Summit 2023
◆Oral PresentationPresentation
Management to participate in panel at Canaccord 43rd Annual Growth Conference
Past FDA Catalysts and PDUFA Decisions
How NAUT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Nautilus Biotechnology, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NAUT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| AH Equity Partners Bio II, L.L.C.10% Owner | Sell | -4,615,974 11,682,032 held | $2.35 | 06/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NAUT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.3 % (-70 %) | 21.76 M | 11.63 M | -7.62% ( -960.00 K) |
NAUT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NAUT ranks across every disease it competes in
Competitive Position is a premium feature
See how NAUT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNAUT News
NAUT▲ +5.4%today
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
Nautilus Biotechnology, Inc. announced it will report its third quarter 2026 financial results on October 27, 2026. The company will hold a conference call to discuss the results and future outlook. This reflects Nautilus's ongoing commitment to transparency and engagement with investors.
Read more →NAUT▼ -27.7%on this news· ran to -41% by day 3
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
Nautilus Biotechnology reported its financial results for Q2 2026, marking its first revenue from grant funding and early access program sales. The company is advancing its proteoform applications, with strong customer interest. Despite a net loss of $14.5 million, Nautilus is reallocating resources to accelerate product development and is on track for future launches.
Read more →NAUT▲ +5.3%on this news
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
Nautilus Biotechnology, Inc. will announce its financial results for the second quarter of 2026 on July 28, 2026. The company will hold a conference call to discuss these results, along with business developments and future outlook. The webcast will be accessible via the company's website.
Read more →NAUTNautilus Biotechnology Reports First Quarter 2026 Financial Results
Nautilus Biotechnology reported its Q1 2026 financial results, highlighting the initiation of an Early Access Program for its Tau proteoform assay. The company saw a decrease in operating expenses and appointed a new VP of Global Sales to enhance customer engagement. Despite a net loss, Nautilus is making strides toward commercialization and platform validation.
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
Nautilus Biotechnology, Inc. will announce its financial results for Q1 2026 on April 28, 2026. The announcement will be made before market open, followed by a conference call to discuss the results and future outlook. The company focuses on advancing proteomics technology to enhance human health.
Read more →NAUT▲ +9.1%on this newsshared move
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
Nautilus Biotechnology, Inc. will participate in the Investor Summit Group Virtual Conference on March 25, 2026. The presentation will be accessible live and archived on their website. Nautilus is focused on developing a technology platform for protein analysis, aiming to advance the field of proteomics.
Read more →NAUTNautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Nautilus Biotechnology has announced Baylor College of Medicine as the inaugural customer for its Voyager Platform through an Early Access Program. The collaboration, supported by the NIH, focuses on leveraging Nautilus' unique single-molecule proteomics method to enhance cancer research by identifying aberrant protein isoforms. This initiative aims to create a comprehensive computational toolkit for better detection of protein isoforms and biomarker analysis. The project represents a significant step towards integrating proteomic data with genomic studies in cancer biology.
Read more →NAUTNautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Nautilus Biotechnology has appointed Amber Faust as Vice President of Sales to lead the commercialization of its Voyager™ Platform. Faust, with nearly two decades of experience in proteomics, will oversee the launch and market introduction of the platform, which aims to enhance single-molecule protein analysis. The company is progressing towards commercialization with its Iterative Mapping Early Access Program and aims for a commercial launch in late 2026.
Read more →NAUT▼ -16.3%on this newsshared move
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Nautilus Biotechnology reported its financial results for Q4 and fiscal year 2025, highlighting a decrease in operating expenses and a net loss reduction. The company is focused on expanding its Early Access Program and aims for commercialization by late 2026. Despite a strong cash position, it anticipates no significant revenue in 2026.
Read more →NAUT▲ +5.2%on this newsshared move
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
Nautilus Biotechnology unveiled its Voyager Platform at the US HUPO 2026 conference, designed for single-molecule proteome analysis. The platform can measure up to 10 billion intact proteins simultaneously, promising to advance proteomics research. An Early Access Program is now open for researchers, with commercial launch anticipated in late 2026.
Read more →NAUT▲ +7.8%on this newsshared move
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology, Inc. has announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026. During the event, Nautilus management will engage in a fireside chat, which can be accessed live and archived on the company's website. Nautilus is focused on revolutionizing the field of proteomics through its innovative platform technology, aiming to enhance understanding and access to the proteome.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Nautilus Biotechnology, Inc. announced it will release its financial results for Q4 and the full year 2025 on February 26, 2026. The company will hold a conference call to discuss these results and its business outlook. This event highlights Nautilus's ongoing developments in the field of proteomics.
Read more →NAUT▼ -5.8%on this newsshared move
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to advance research on alpha-synuclein in Parkinson's disease. The collaboration, supported by a $1.6 million grant, aims to develop a single-molecule assay to measure various proteoforms of alpha-synuclein. This research could improve understanding of the disease and enhance biomarker development for clinical trials.
Read more →NAUTNautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Nautilus Biotechnology has launched an Early Access Program for its novel proteomics platform, starting with a tau proteoforms assay aimed at Alzheimer’s research. This initiative allows selected researchers to utilize Nautilus' Iterative Mapping method, which provides high-resolution insights into protein variations. The company emphasizes that its platform delivers unique capabilities compared to traditional proteomics methods. Initial validation and positive feedback from research partners demonstrate the platform's potential impact on advancing neurodegenerative biology studies.
Read more →NAUT▲ +5.2%on this news
Nautilus at HUPO 2025 – Redefining proteomics with single-molecule Iterative Mapping
Nautilus Biotechnology presented its innovative Iterative Mapping technology at HUPO 2025 in Toronto, emphasizing its ability to enhance proteomic analysis by providing both breadth and detail. Professor Birgit Schilling showcased novel data on tau proteoforms in Alzheimer's research, marking a significant milestone for the Nautilus Platform. The positive reception from the audience underscored the platform's potential to advance understanding in proteomics.
Read more →NAUT▲ +39.1%on this newsshared move
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
Nautilus Biotechnology has successfully installed its first external field evaluation unit at the Buck Institute for Research on Aging. This milestone allows independent labs to access Nautilus' single-molecule proteomics platform, generating reproducible data on tau proteoforms related to neurodegenerative diseases. The collaboration aims to advance research on Alzheimer's disease, with initial findings set to be presented at the 2025 HUPO World Congress.
Read more →NAUT▲ +5.9%on this newsshared move
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
Nautilus Biotechnology reported its financial results for Q3 2025, highlighting a 19% reduction in operating expenses and a net loss of $13.6 million. The company is focused on launching its early access program for Tau proteoforms in 2026, aiming for full commercialization by late 2026. Nautilus currently holds $168.5 million in cash and investments.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
Nautilus Biotechnology, Inc. is set to announce its financial results for the third quarter of 2025 before the market opens on October 28, 2025. The announcement will be followed by a conference call at 5:30 a.m. Pacific Time, where management will discuss the results and future outlook. Nautilus focuses on developing a platform technology aimed at unlocking the complexity of the proteome, which is integral to advancements in health and medicine.
Read more →About Nautilus Biotechnology, Inc.
Headquarters2701 EASTLAKE AVE EAST, SEATTLE, WA, 98102
BIOPHARMAWATCH ELITE PLUS
Trade the next NAUT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime